A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants.

Aboulkassim T, Tian X, Liu Q, Qiu D, Hancock M, Wu JH, Batist G
Cell Rep. 2023 Sep 26;42(9):113104. doi: 10.1016/j.celrep.2023.113104. Epub 2023 Sep 12. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.